PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)

被引：0
|
作者：
Liu, S. -Y. M. [1 ,2 ]
Deng, J. -Y. [3 ]
Yan, H. -H. [3 ]
Yang, M. -Y. [3 ]
Xu, C. -R. [3 ]
Zheng, M. -Y. [3 ]
Gan, B. [3 ]
Zhang, X. -C. [3 ]
Tu, H. -Y. [3 ]
Yang, J. -J. [3 ]
Chen, H. -J. [3 ]
Wang, B. -C. [3 ]
Li, Y. [1 ,4 ]
Zhou, Q. [2 ,3 ]
Wu, Y. -L. [2 ,3 ]
机构：
[1] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China
[2] Chinese Thorac Oncol Grp CTONG, Guangzhou, Peoples R China
[3] Southern Med Univ, Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Peoples R China
[4] Jinan Univ, Sch Med, Inst Hematol, Key Lab Regenerat Med,Minist Educ, Guangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
non-small cell lung cancer; pembrolizumab; sintilimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
WS02.13
引用
收藏
页码：S38 / S39
页数：2
相关论文
共 50 条
  • [1] PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial
    Liu, Si-Yang Maggie
    Huang, Jie
    Deng, Jia-Yi
    Xu, Chong-Rui
    Yan, Hong-Hong
    Yang, Ming-Yi
    Li, Yang-Si
    Ke, E-e
    Zheng, Ming-Ying
    Wang, Zhen
    Lin, Jia-Xin
    Gan, Bin
    Zhang, Xu-Chao
    Chen, Hua-Jun
    Wang, Bin-Chao
    Tu, Hai-Yan
    Yang, Jin-Ji
    Zhong, Wen-Zhao
    Li, Yangqiu
    Zhou, Qing
    Wu, Yi-Long
    SCIENCE BULLETIN, 2024, 69 (04) : 535 - 543
  • [2] Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression
    Miyakoshi, Jun
    Yoshida, Tatsuya
    Kashima, Jumpei
    Shirasawa, Masayuki
    Torasawa, Masahiro
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Shiraishi, Kouya
    Kohno, Takashi
    Yamamoto, Noboru
    Yatabe, Yasushi
    Suzuki, Takuji
    Ohe, Yuichiro
    LUNG CANCER, 2024, 191
  • [3] PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater
    Itani, H.
    Nigi, A.
    Iwamoto, K.
    Ito, Y.
    Tanigawa, M.
    Kondo, S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S662 - S663
  • [4] PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
    Di Federico, Alessandro
    De Giglio, Andrea
    Parisi, Claudia
    Gelsomino, Francesco
    Ardizzoni, Andrea
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [5] Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
    Shinobu Hosokawa
    Eiki Ichihara
    Daijiro Harada
    Shoichi Kuyama
    Koji Inoue
    Kenichi Gemba
    Hirohisa Ichikawa
    Yuka Kato
    Naohiro Oda
    Isao Oze
    Tomoki Tamura
    Toshiyuki Kozuki
    Takahiro Umeno
    Toshio Kubo
    Katsuyuki Hotta
    Akihiro Bessho
    Yoshinobu Maeda
    Katsuyuki Kiura
    International Journal of Clinical Oncology, 2022, 27 : 1139 - 1144
  • [6] Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801
    Hosokawa, Shinobu
    Ichihara, Eiki
    Harada, Daijiro
    Kuyama, Shoichi
    Inoue, Koji
    Gemba, Kenichi
    Ichikawa, Hirohisa
    Kato, Yuka
    Oda, Naohiro
    Oze, Isao
    Tamura, Tomoki
    Kozuki, Toshiyuki
    Umeno, Takahiro
    Kubo, Toshio
    Hotta, Katsuyuki
    Bessho, Akihiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1139 - 1144
  • [7] Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
    Chen, Ya
    Wang, Yanan
    Yang, Zhengyu
    Hu, Minjuan
    Zhang, Yanwei
    Qian, Fangfei
    Zhang, Wei
    Zhang, Bo
    Han, Baohui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
    Takumida, Hiroshi
    Horinouchi, Hidehito
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Yoshida, Tatsuya
    Goto, Yasushi
    Yamamoto, Noboru
    Ohe, Yuichiro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (03) : 737 - 746
  • [9] Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
    Hiroshi Takumida
    Hidehito Horinouchi
    Ken Masuda
    Yuki Shinno
    Yusuke Okuma
    Tatsuya Yoshida
    Yasushi Goto
    Noboru Yamamoto
    Yuichiro Ohe
    Cancer Immunology, Immunotherapy, 2022, 71 : 737 - 746
  • [10] Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC
    Melosky, B.
    Chu, Q.
    Juergens, R. A.
    Leighl, N.
    Lonescu, D.
    Tsao, M. -S.
    McLeod, D.
    Hirsh, V.
    CANCER TREATMENT REVIEWS, 2018, 65 : 65 - 77
12345